Keytruda plus Lenvima have received FDA approval as first-line treatment of adult patients with advanced renal cell carcinoma.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
